NARI Earnings Prediction
The chart below shows how NARI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NARI sees a +1.85% change in stock price 10 days leading up to the earnings, and a +1.86% change 10 days following the report. On the earnings day itself, the stock moves by +0.17%. This data can give you a slight idea of what to expect for the next quarter's release.
NARI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
153.39M
21.39%
5.19%
Gross Margin
85.43%
-3.51%
0.97%
Operating Margin
-4.34%
-359.88%
-59.63%
Net Margin
-11.97%
-578.80%
-44.33%
EPS
-0.31
-720.00%
-42.59%
No Data Available
NARI Earnings Analysis
Inari Medical, Inc. Common Stock Corporation (NARI.O) Earnings Conference Call
Positive
Record Revenue Increase: In Q3, Inari reported record revenue of $153.4 million, reflecting a 21.4% increase year-over-year.
VTE Revenue Increase: Global VTE revenue in Q3 was $145.3 million, up 19.7% compared to the same period last year.
Q3 Revenue Surge: Global Emerging Therapies revenue in Q3 was $8 million, representing a 64% increase over the prior year.
International Revenue Surge: International revenue reached $11.5 million, marking a 76.4% increase compared to the previous year.
Revenue Guidance Increase: The company raised its full-year 2024 revenue guidance to between $601.5 million and $604.5 million, indicating a growth of 22% to 22.5% over 2023.
Negative
Operating Loss Comparison: In Q3, Inari reported a GAAP operating loss of $13.6 million compared to a GAAP operating income of $2.1 million for the same period in the prior year.
Operating Expenses Increase: Operating expenses were $147.1 million in the third quarter of 2024 compared with $109.8 million for the same period in the prior year.
R&D Expense Increase: R&D expense was $29.4 million in the third quarter of 2024 compared with $21.5 million for the same period of 2023.
Net Loss Per Share: The basic and fully diluted net loss per share for the third quarter of 2024 was $0.31 on a weighted average basic and diluted share count of $58.4 million, compared with a basic and fully diluted net income per share of $0.06 and $0.05 on a weighted average basic and diluted share count of $57.4 million and $58.6 million, respectively, in the same period of the prior year.
Net Loss Comparison: Net loss was $18.4 million for the third quarter of 2024 compared to a net income of $3.2 million for the same period of the prior year.
NARI FAQs
How does NARI typically perform around its earnings report dates?
Is Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NARI Earning Call Sentiment
Inari Medical, Inc. (NARI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NARI.O
0%Positive
The earnings call presents mixed signals. Financial performance shows strong revenue growth but also increased operating losses, which is concerning. The Q&A section reveals stable market health and growth potential, but management's vague responses on certain topics may raise investor concerns. The lack of a shareholder return plan and declining gross margins also contribute to a neutral outlook. However, the raised annual revenue guidance and robust growth in emerging therapies offer positive aspects, balancing the negative elements. Given the company's market cap, the stock price is likely to remain stable over the next two weeks.
